disclosed on Friday that its Chief Executive Officer, Dr. Vikas Gupta, has resigned from the position to pursue new professional opportunities.
Dr. Gupta will remain in his role until June 30, 2026, to ensure a smooth handover of ongoing strategic initiatives and leadership responsibilities. No successor has been named as yet.
Markets reacted negatively to the announcement. Alkem’s shares on the NSE fell ₹154.50, or 2.80 per cent, to ₹5,366 as of afternoon trade on Friday, against a previous close of ₹5,520.50. Sell orders significantly outpaced buy orders, with 61 per cent of queued quantity on the sell side. The stock touched an intraday low of ₹5,355, though it remains above its 52-week low of ₹4,716.20 recorded in July 2025.
In his resignation letter, Dr. Gupta cited personal and long-term professional goals as reasons for his departure. He described the decision as difficult and credited his tenure with strengthening Alkem’s market position and advancing its research and development pipeline. He also acknowledged the support of the promoter family and the board.
Alkem Laboratories, a constituent of the Nifty Midcap 50 index, carries a total market capitalisation of approximately ₹64,111 crore. The stock trades at a price-to-earnings ratio of around 27.